Diana Campelo Delgado,  —

Dosing has begun in a Phase 1 clinical trial testing Inhibikase Therapeutics’ investigational oral therapy IkT-148009 for Parkinson’s disease and related disorders in healthy volunteers. This first clinical trial (NCT04350177) is expected to enroll 112 healthy adults, ages 45 to 70, at a single site in…

The Sheffield Institute for Translational Neuroscience, known as SITraN, has joined with Verge Genomics to develop new therapeutic targets and screen the latest compounds for the treatment of neurodegenerative disorders such as Parkinson’s disease. The aim of this partnership is to accelerate the validation of new therapeutic candidates…

Researchers from Malmö University in Sweden are developing an interactive digital health tool, called Parkapp, to monitor symptoms and help diagnose Parkinson’s disease. The mobile app is able to monitor finger movements, voice samples and motion patterns as the conventional smartphone screen is tapped, making it possible to gather…

Insightec announced that its incision-free brain “surgery” technology — called Exablate 4000 (Exablate Neuro) — has been approved in China to treat essential tremor and tremors caused by Parkinson’s disease. The market approval from China’s regulatory agency for medicines and medical devices, the National Medical Products Administration, will allow the…

Alterity Therapeutics has been awarded a grant from the Michael J. Fox Foundation (MJFF) for animal studies to determine the optimal dose its of lead candidate ATH434, an essential step to opening trials in people with Parkinson’s disease. “I look forward to seeing the results from the…

The first Parkinson’s disease patient has been implanted with Newronika‘s AlphaDBS, an innovative deep brain stimulation (DBS) system, in a clinical trial conducted in Italy and Poland. DBS is an established treatment for people with Parkinson’s disease who do not respond adequately to medication. It is a surgical procedure…

Brain Neurotherapy Bio (BNB) has joined with Asklepios BioPharmaceutical (AskBio), a merger aiming to expand a gene therapy program for progressive neurodegenerative diseases such as Parkinson’s and multiple system atrophy (MSA), a form of atypical parkinsonism. “I’m pleased to welcome the Brain Neurotherapy Bio team to AskBio,” Sheila…

Manus Neurodynamica, a medical technology company, has raised £1.2 million ($1.6 million) to launch NeuroMotor, a digital pen with a patented sensor technology that can help diagnose patients with Parkinson’s disease and other movement disorders. This financing round will allow the NeuroMotor Pen to be launched in…

Microba has partnered with researchers at the University of Queensland’s (UQ) Faculty of Medicine to study gut bacteria of people with Parkinson’s disease, with a goal of discovering and developing new biomarkers and therapies for this neurodegenerative disorder. A first clinical trial is planned for this year at sites…

A branch of the National Institutes of Health has awarded a $3.1 million, multiyear grant to a research team to study changes in speech, and look at movement, in Parkinson’s patients given bilateral deep brain stimulation (DBS). The grant from the National Institute on Deafness and other Communication Disorders (NIDCD) was…